Evidence map›Paper›PMID 39928060›Full record

ArticleJournal of fluorescence2025

Antibody and Aptamer-Based Magnetic-Graphene Oxide Desorption (M-GOD) Quantum Dot Assays for Rapid and Sensitive Detection of SAR-CoV-2.

Asma Mirza, John Marino, Jerry Aguren, John G Bruno

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asma MirzaSteradian Technologies, Inc., 2450 Holcombe Street. Suite J, Houston, TX, 77021, USA.
John MarinoSteradian Technologies, Inc., 2450 Holcombe Street. Suite J, Houston, TX, 77021, USA.
Jerry AgurenSteradian Technologies, Inc., 2450 Holcombe Street. Suite J, Houston, TX, 77021, USA.
John G BrunoNanohmics, Inc., 6201 E. Oltorf Street. Suite 400, Austin, TX, 78741, USA. jbruno@nanohmics.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid detection of respiratory diseases using a noninvasive bind-and-detect breath test could shift the future of rapid diagnostics. Commercially available biotinylated anti-SARS-CoV-2 spike (S) protein antibody was conjugated to streptavidin-coated quantum dots, purified, and adsorbed onto magnetic-graphene oxide (M-GO) flakes to quench the conjugate. When inactivated SARS-CoV-2 was added at increasing levels, the antibody-quantum dot conjugates desorbed from the M-GO as a function of virus concentration with an apparent limit of detection ~ 9,600 inactivated virus particles within 2-5 min in phosphate-buffered saline (PBS) plus 10 mM Mg

Indexed as

Antibodies, ViralAptamers, NucleotideCOVID-19GraphiteQuantum DotsSARS-CoV-2Biosensing TechniquesHumansLimit of DetectionSpike Glycoprotein, CoronavirusAntibodies, ViralAptamers, Nucleotidegraphene oxideGraphiteSpike Glycoprotein, CoronavirusAntibodyAptamerCOVIDGraphene oxideMagneticQuantum dotSARS-CoV-2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.